Daily Roundup

IEL.ASX CYP.ASX XRG.ASX PLS.ASX LIN.ASX

IDP Education returns capital to shareholders

IDP Education Ltd has released a trading update for the period ending June 2026 alongside an announcement of a share buy-back program. The price-sensitive announcement signals the company's intention to return capital to shareholders as it continues navigating the international education market.

Cynata's osteoarthritis trial disappoints

Cynata Therapeutics has reported underwhelming results from its Phase 3 SCUlpTOR trial of CYP-004, an iPSC-derived treatment for knee osteoarthritis. While the trial identified no safety concerns, it found no statistically significant differences between the active treatment and control groups in primary endpoints. The real surprise came from the control group, which showed higher-than-expected pain reduction, and there was no evidence of cartilage loss reduction in the treatment group. CEO Dr. Kilian Kelly expressed disappointment and flagged that the company is now reviewing further development options for its Cymerus technology platform.

The biotech company's securities have since been reinstated on the ASX following the announcement. Investors should expect continued volatility as the market absorbs these results, with a Phase 2 Graft versus Host Disease trial still pending.

Xreality partners with Thales Australia

XReality Group's Operator XR subsidiary has signed a Memorandum of Understanding with Thales Australia to collaborate on training and simulation programs for defence, security, and law enforcement markets. The reciprocal partnership allows either party to lead or support initiatives, combining Thales's global reach with Operator XR's regional market penetration. The collaboration targets enhanced operational readiness and safety across the Asia-Pacific region and beyond.

Pilbara Minerals moves forward on lithium expansion

Pilbara Minerals has approved approximately $175 million in pre-final investment decision capital expenditure for its P2000 Project at the Pilgangoora Operation. The spending focuses on processing plant procurement and engineering, on-site early works, and infrastructure development, with outcomes expected by the end of 2026. The company is targeting first ore in mid-2029, contingent on positive study outcomes, funding capacity, and market conditions. The investment reflects Pilbara's confidence in long-term lithium demand and its strategy to address potential supply-side constraints.

Lindian Resources takes control of sales

Lindian Resources has terminated its sale agreement with Gerald Metals for monazite concentrate supply from its Kangankunde Rare Earths Project in Malawi. The mutual termination, which ends an arrangement signed in September 2023, gives Lindian full control over its sales pipelines, pricing, and profitability. As part of the deal, Lindian will issue 20 million fully paid ordinary shares to Gerald within 14 days, subject to a 90-day voluntary escrow. The move positions Lindian to accelerate product supply to its SARECO hydromet facility in Kazakhstan.